Trabeculectomy with Ologen implant versus perfluoropropane gas bubble for open angle glaucoma in pseudophakic eyes

Elwehidy, Ahmed S; Mokbel, Tharwat H; Abouelkheir, Hossam Youssef; Samra, Waleed Abou; Wagdy, Faried M; Abdelkader, Amr

doi:10.18240/ijo.2021.04.05

Cited by 2 publications

(1 citation statement)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Animal studies and pilot human studies have shown safe and promising results in the early post-op period as well as long-term IOP control [ 50 ]. Thus, injection of C3F8 gas at the time of glaucoma filtering surgery may be a promising technique for increasing bleb survival and reducing fibrosis [ 183 ].…”

Section: Strategies To Prevent Ocular Fibrosis Following Glaucoma Fil...mentioning

confidence: 99%

Novel Therapies for the Prevention of Fibrosis in Glaucoma Filtration Surgery

et al. 2023

View full text Add to dashboard Cite

Conjunctival fibrosis remains the major impediment to the success of glaucoma filtration surgery. Anti-metabolites remain the gold standard for mitigating post-surgical fibrosis, but they are associated with high complication rates and surgical failure rates. Establishing a more targeted approach to attenuate conjunctival fibrosis may revolutionize the surgical approach to glaucoma. A new strategy is needed to prevent progressive tissue remodeling and formation of a fibrotic scar, subsequently increasing surgical success and reducing the prevalence of glaucoma-related vision loss. Advancements in our understanding of molecular signaling and biomechanical cues in the conjunctival tissue architecture are broadening the horizon for new therapies and biomaterials for the mitigation of fibrosis. This review aims to highlight the strategies and current state of promising future approaches for targeting fibrosis in glaucoma filtration surgery.

show abstract

Section: Strategies To Prevent Ocular Fibrosis Following Glaucoma Fil...mentioning

confidence: 99%

Novel Therapies for the Prevention of Fibrosis in Glaucoma Filtration Surgery

et al. 2023

View full text Add to dashboard Cite

show abstract

Clinical Impact of the Use of Ologen in Filtering Surgery Performed in Uncontrolled Glaucoma

Navero-Rodríguez,

Boldú-Roig,

Pinilla

et al. 2024

JCM

View full text Add to dashboard Cite

Introduction: To compare the efficacy and safety of trabeculectomy with a collagen matrix implant (Ologen®) versus trabeculectomy with mitomycin C (MMC) versus trabeculectomy with both Ologen® and MMC (OLO + MMC). Methods: This non-randomized study included 119 eyes of 101 patients with uncontrolled open-angle glaucoma who underwent trabeculectomy, either alone or combined with phacoemulsification. The data were initially recorded following a standard surgical protocol, using an electronic database with structured fields. The patients were divided into three groups: 44 received trabeculectomy with adjunctive MMC (MMC group), 34 received surgery with Ologen® (OLO group), and 41 received surgery with both Ologen® and MMC (OLO + MMC group). The main outcome measures were the change in intraocular pressure (IOP), change in number of medications needed, complete success rate (defined as IOP ≤ 20 mmHg and at least 20% IOP reduction without hypotensive medications), rate of complications, and rate of postoperative interventions. The follow-up period was 36 months. Results: IOPs significantly decreased (p = 0.01) in all groups across all study visits, decreasing from 19.8 ± 4.6 mmHg to 12.7 ± 4.2 mmHg in the MMC group, from 20.5 ± 4.7 mmHg to 13.9 ± 3.5 mmHg in the OLO group, and from 23.5 ± 6.1 mmHg to 13.1 ± 3.5 mmHg in the OLO + MMC group. After correcting for the baseline IOP, only the first two postoperative visits (first week and first month) showed a significantly greater IOP reduction in the OLO + MMC group. The number of hypotensive medications was significantly reduced from 3.1 ± 0.6 to 0.56 ± 1.1 in the MMC group, from 2.9 ± 0.4 to 0.83 ± 1.1 in the OLO group, and from 3.0 ± 0.6 to 0.45 ± 0.95 in OLO + MMC group, with no statistically significant differences among the groups (p = 0.57). The complete success rates were 63.6% in the MMC group, 67.6% in the OLO group, and 80.5% in the OLO +MMC group, with no statistically significant differences between the groups (p = 0.21). Suture release was significantly more frequent in the MMC group (86.1%) than in the OLO group (62.1%) and in the OLO + MMC group (45.9%; p = 0.02). Bleb needling, with (33.3%; p = 0.005) or without (66.7%; p = 0.0001) 5-fluorouracil injection (5-FU), was significantly more common in the MMC group. The highest complete success rate (61%) was observed in the OLO + MMC group. Conclusions: The use of Ologen® and mitomycin C provided similar surgical IOP reduction in glaucoma surgery compared with either MMC or Ologen® alone, but significantly reduced the need for postoperative interventions.

show abstract

Trabeculectomy with Ologen implant versus perfluoropropane gas bubble for open angle glaucoma in pseudophakic eyes

Cited by 2 publications

References 15 publications

Novel Therapies for the Prevention of Fibrosis in Glaucoma Filtration Surgery

Novel Therapies for the Prevention of Fibrosis in Glaucoma Filtration Surgery

Clinical Impact of the Use of Ologen in Filtering Surgery Performed in Uncontrolled Glaucoma

Contact Info

Product

Resources

About